Search

Your search keyword '"Matsuda, Mitsuhiro"' showing total 665 results

Search Constraints

Start Over You searched for: Author "Matsuda, Mitsuhiro" Remove constraint Author: "Matsuda, Mitsuhiro"
665 results on '"Matsuda, Mitsuhiro"'

Search Results

1. The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients

2. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)

3. Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)

4. Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum

5. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

11. Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial

14. Dasatinib-based 2-step induction for adults with Philadelphia chromosome–positive acute lymphoblastic leukemia

17. Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial

20. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)

21. Recapitulating the human segmentation clock with pluripotent stem cells

22. Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)

24. Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum

25. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

26. Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum

27. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

29. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

30. A stem cell zoo uncovers intracellular scaling of developmental tempo across mammals

38. This title is unavailable for guests, please login to see more information.

39. Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis

40. Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma

41. Novel prognostic predictor of haemoglobin–platelet index in diffuse large B‐cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL ‐6 production in lymphoma cells

42. sj-docx-13-tah-10.1177_20406207221142487 – Supplemental material for Monocyte or white blood cell counts and β2 microglobulin predict the durable efficacy of daratumumab with lenalidomide

48. Decreased expression of T‐cell‐associated immune markers predicts poor prognosis in patients with follicular lymphoma

49. Anti-early endosome antigen 1 autoantibodies were detected in a pemphigus-like patient but not in the majority of pemphigus diseases

50. Anti‐desmoglein 1 antibody‐positive mother and antibody‐negative child with Darier's disease.

Catalog

Books, media, physical & digital resources